A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC

NCT05896059 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Extensive Stage Small Cell Lung Cancer

Interventions

DRUG: Tislelizumab
DRUG: Anlotinib

Sponsor

Zhejiang Cancer Hospital